Other studies indicated, however, that CTGF can exert profibrotic effects [131], and that CTGF inhibition with monoclonal antibodies enhances cardiac repair, limits fibrosis, and ensures better preservation of left ventricular systolic function post-myocardial infarction [132]. This evidence concerns the gene CCN2 and myocardial infarction.